Article
Author(s):
Cemiplimab is a recombinant human immunoglobulin G4 monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
Medication Pearl of the Day: Cemiplimab (Libtayo)
Indication: For cutaneous squamous cell carcinoma (CSCC), for the treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC, for basal cell carcinoma, and non-small cell lung cancer.
Insight:
Source:
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma